Latest Breaking News On - Tenax therapeutics inc - Page 1 : comparemela.com

Tenax Therapeutics, Inc (NASDAQ:TENX) Sees Significant Drop in Short Interest

Tenax Therapeutics, Inc (NASDAQ:TENX) Sees Significant Drop in Short Interest
modernreaders.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernreaders.com Daily Mail and Mail on Sunday newspapers.

United statesRoth mkmTenax therapeutics company profileTenax therapeutics incTenax therapeuticsGet free reportTenax therapeutics daily

Tenax Therapeutics, Inc (NASDAQ:TENX) Short Interest Down 56 3% in May

Tenax Therapeutics, Inc (NASDAQ:TENX) Short Interest Down 56 3% in May
modernreaders.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernreaders.com Daily Mail and Mail on Sunday newspapers.

United statesRoth mkmTenax therapeutics company profileTenax therapeutics incTenax therapeuticsGet free reportTherapeutics trading downTenax therapeutics daily

Tenax Therapeutics, Inc (NASDAQ:TENX) Short Interest Down 36 4% in April

Tenax Therapeutics, Inc (NASDAQ:TENX) Short Interest Down 36 4% in April
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Roth mkmTenax therapeutics company profileTenax therapeutics incTenax therapeuticsGet free reportTenax therapeutics daily

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesBrian mullenChris giordanoJohn frauncesJaved butlerDaniel burkhoffSanjiv shahNasdaq stock marketResearch for the bluhm cardiovascular instituteOrion corporationLifesci advisorsTenax therapeutics incMd northwestern universityTrademark officeCardiovascular research foundation technologyGlobal development

Tenax Therapeutics Announces New U S Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Represents the third patent granted to Tenax since March of 2023 protecting the use of levosimendan in the treatment of PH-HFpEF

United statesChris giordanoOrion corporationTenax therapeutics incTrademark officeTenax therapeuticsUnited states patentChief executive officerTenax therapeutic phaseTenax therapeutic